Manmath Patekar

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Iain B. McInnes, Philip J. Mease, Bruce Kirkham et al. · The Lancet · 2015 · 850 citations

Life Sciences, Immunology, Pharmacotherapy +15

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (<scp>SCULPTURE</scp> Extension Study)

Robert Bissonnette, Thomas A. Luger, Diamant Thaçi et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 193 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

Christine Bodemer, Andrzej Kaszuba, Külli Kingo et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 94 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

Boni E. Elewski, John W. Baddley, Atul Deodhar et al. · JAMA Dermatology · 2020 · 77 citations · Full text

Medicine, Immunology, Pharmacology +13

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

Jerry Bagel, John K Nia, Peter W. Hashim et al. · Dermatology and Therapy · 2018 · 75 citations · Full text

Medicine, Dermatology, Pharmacotherapy +11